نتایج جستجو برای: آمینواتیلیدین alfa
تعداد نتایج: 18591 فیلتر نتایج به سال:
The likelihood of a sustained virological response (SVR) is the most important factor for physicians and patients in the decision to initiate and continue therapy for chronic hepatitis C (CHC) infection. This study identified predictive factors for SVR with peginterferon plus ribavirin (RBV) in patients with CHC treated under 'real-life' conditions. The study cohort consisted of patients from a...
Fabry disease is an X-linked lysosomal storage disorder caused by inherited deficiency of the enzyme a-galactosidase A. Enzyme replacement treatment using agalsidase alfa significantly reduces pain, improves cardiac function and quality of life, and slows renal deterioration. Nevertheless, it is a life-long treatment which requires regular intravenous infusions and entails a great burden for pa...
Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interf...
Recently, recombinant DNA methods have been successfully applied to interferon production, making adequate quantities available for both in vitro and in vivo testing. Although interferons are in the class of biologic response modifiers, they do have some direct cytotoxic effects on human tumor cells that can be quantitated in vitro with the colony-forming assay. In the clonogenic assay, RPMI-82...
C infections with the hepatitis C virus (HCV) represent a major global health problem, with around 170 million patients at risk of developing life-threatening complications such as liver cirrhosis or hepatocellular carcinoma. The standard treatment of care is a combination of weekly pegylated interferon (peginterferon) alfa and daily ribavirin for 24-72 weeks, dependent on HCV genotype and the ...
Project Acronym : X-act Project Start Date : 1st October, 2012 Consortium : UNIVERSITY OF PATRAS (LMS) Project Coordinator COMAU SPA (COMAU) SIEMENS INDUSTRY SOFTWARE SAS (SIEMENS-PLM) FUNDACION TEKNIKER (TEKNIKER) FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V (F-IPK) TOFAS TURK OTOMOBIL FABRIKASI ANONIM SIRKETI (TOFAS) ALFA HOGAR S.L. (ALFA) PILZ INDUSTRIEELEKTRONIK SL (...
INTRODUCTION Anosmia, the loss of the sense of smell, is a rare adverse event associated with interferon alpha (INF-α). Millions of patients with hepatitis B and hepatitis C virus (HCV) infection are currently treated with INF-alfa-2a daily. Only 5 cases of anosmia have been reported in the literature, and none was associated with pegylated INF-alfa. CASE SUMMARY A 55-year-old Arab male (heig...
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients with severe sepsis. Despite its therapeutic promise, treatment with drotrecogin alfa (activated) represents a new challenge for many clinicians and health care centers. Specifically, optimizing the appropriate role for drotrecogin alfa (activated) requires balancing numerous issues, including its...
The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives ( approximately 24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections are inconvenient for both the patient and the healthcare provider. With the introduction of ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید